| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2023 | 483.66% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 08/24/2023 | 250.19% | Wedbush | → $9 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 483.66% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/25/2023 | 222.96% | EF Hutton | → $8.3 | Assumes | → Buy |
| 05/12/2023 | 289.11% | B of A Securities | $9 → $10 | Maintains | Buy |
| 05/11/2023 | 483.66% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 03/24/2023 | 222.96% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 03/23/2023 | 250.19% | B of A Securities | → $9 | Reiterates | Buy → Buy |
| 03/23/2023 | 483.66% | HC Wainwright & Co. | $20 → $15 | Reiterates | → Buy |
| 02/27/2023 | 222.96% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 02/17/2023 | 222.96% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 01/30/2023 | 211.28% | B of A Securities | $9 → $8 | Maintains | Buy |
| 12/05/2022 | 222.96% | EF Hutton | → $8.3 | Initiates Coverage On | → Buy |
| 06/02/2022 | 678.21% | HC Wainwright & Co. | → $20 | Assumes | → Buy |
| 05/11/2022 | 561.48% | SVB Leerink | $18 → $17 | Maintains | Outperform |
| 11/19/2021 | 989.49% | SVB Leerink | $29 → $28 | Maintains | Outperform |
| 09/10/2021 | 911.67% | B of A Securities | → $26 | Initiates Coverage On | → Buy |
| 05/25/2021 | 794.94% | Evercore ISI Group | → $23 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 1028.4% | SVB Leerink | → $29 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 756.03% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 05/25/2021 | 1145.14% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
What is the target price for Werewolf Therapeutics (HOWL)?
The latest price target for Werewolf Therapeutics (NASDAQ: HOWL) was reported by HC Wainwright & Co. on September 15, 2023. The analyst firm set a price target for $15.00 expecting HOWL to rise to within 12 months (a possible 483.66% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Werewolf Therapeutics (HOWL)?
The latest analyst rating for Werewolf Therapeutics (NASDAQ: HOWL) was provided by HC Wainwright & Co., and Werewolf Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Werewolf Therapeutics (HOWL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Werewolf Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Werewolf Therapeutics was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.
Is the Analyst Rating Werewolf Therapeutics (HOWL) correct?
While ratings are subjective and will change, the latest Werewolf Therapeutics (HOWL) rating was a reiterated with a price target of $0.00 to $15.00. The current price Werewolf Therapeutics (HOWL) is trading at is $2.57, which is within the analyst's predicted range.